Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Jan 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called Al18F-NOTA-Pentixafor PET/CT, which may help doctors better understand and treat a condition known as primary aldosteronism. This condition occurs when the adrenal glands produce too much aldosterone, a hormone that can affect blood pressure and heart health. The trial aims to see how safe this imaging technique is, how well it works, and whether it can help guide surgical decisions for patients with adrenal masses that are suspected to be causing their symptoms.

To participate in the study, you would need to be between the ages of 65 and 75 and have been diagnosed with primary aldosteronism or have adrenal masses based on previous imaging tests. You would also need to be willing to sign a consent form and follow the study's procedures. However, some people may not be eligible, such as those with serious health issues or certain other conditions. If you join, you'll undergo PET imaging, and the trial will monitor your safety throughout the process. This research could lead to better ways to diagnose and treat this condition in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with adrenal masses suspected to be aldosterone-producing adenomas based on routine imaging (e.g., CT scans), or clinically diagnosed primary aldosteronism patients requiring subtyping
• • 2. Signed written informed consent, with willingness and ability to comply with study procedures.
• • 3. Female participants must be surgically sterilized or postmenopausal for over a year; if not, reliable contraception is required.
• • 4. Male participants must use reliable contraception during the study and refrain from sperm donation.
• Exclusion Criteria:
• • 1. Severe neurological disorders, or any significant diseases affecting the gastrointestinal, cardiovascular, hepatic, renal, hematological, oncological, endocrine, respiratory, or immune systems, or other serious illnesses.
• • 2. Diagnosis of claustrophobia.
• • 3. History of drug abuse or alcohol dependence.
• • 4. Pregnant or breastfeeding women.
• • 5. Poor venous access that would preclude repeated venipuncture.
• • 6. Use of experimental drugs or devices within one month prior to the study, where the safety or efficacy has not been established.
• • 7. Any condition that the study investigators deem could pose potential harm or jeopardize participant safety.